Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

Merck has development and commercialization agreements with AstraZeneca, Daiichi Sankyo, and LaNova. It also has collaboration agreements with Bayer, Eisai, Moderna, and Ridgeback Biotherapeutics.

are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo.